Projects overview

Sort by

Toggle all information

RESTORE | NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION

01-01-2018

-

30-06-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

ORTHOUNION | ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs

01-01-2017

-

30-06-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

ReGenHeart | Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina A phase II randomized, double-blinded, placebo-controlled study

01-01-2017

-

31-12-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

MAXIBONE | Personalised maxillofacial bone regeneration

01-01-2018

-

30-06-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

PACE | A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

01-01-2017

-

31-12-2021

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

HIPGEN | Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial

01-01-2018

-

30-09-2022

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine

RESPINE | REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy

01-01-2017

-

30-06-2023

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2017-Single-Stage-RTD
SC1-PM-11-2016-2017 Clinical research on regenerative medicine
Powered by Chris Decubber BV